Halozyme Therapeutics' sales jumped 39.2% last quarter, and the company raised its full-year forecast.

Nov 5, 2026, 7:04 PM ETResultsRead the original at marketscreener.com

Good for HALO

Sales rose 39%, royalties rose 44%, and Halozyme raised its full-year sales and profit forecasts. Quarterly profit per share beat analysts' estimates, with no reported setback to counter these gains.

HALO · Halozyme Therapeutics, Inc.

AI read · Good for HALO

The AI's read

Royalties from partner drug sales grew faster than total sales, adding support to the higher company forecast. Quarterly profit per share also beat analysts' estimates. The report gives no setback that counters these gains.

Get alerts for HALO

Follow Halozyme Therapeutics, Inc. (HALO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for HALO

Free on the App Store and Google Play, or on the web.